According to a recent report by Mordor Intelligence, thegeneric injectablesmarketsize is valued at USD 131.68 billion in 2025 and is projected to surpass USD 251.03 billion in 2030, at a 13.78%CAGR through the forecast period 2025-2030, supported by growing demand for affordable biologic and small-molecule therapies. As healthcare systems worldwide continue to manage escalating treatment costs, generic injectableshaveemergedas a cornerstone in ensuring accessibility and affordability of life-saving medications.
https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg
Thegeneric injectables marketbenefits from a strong pipeline of patent expirations and increasing investments in sterile manufacturing. The global shift toward hospital-based care and the rising prevalence of chronic and infectious diseases further reinforce the adoption of injectable generics. Biopharmaceutical firms are expanding their generic injectable portfolios, focusing on oncology, cardiovascular, and anti-infective segments, where injectables dominate clinical use.
Market GrowthDrivers
— Patent Expiry Wave of Blockbuster Drugs:Numerous biologics and branded injectables losing exclusivity are opening new revenue opportunities for generic manufacturers.
— Increasing Contract Manufacturing:CDMOs expandcapacityto meet rising global demand, ensuringtimelysupply.
— Manufacturing Advancements:Improvements in aseptic filling, lyophilization, and cold-chainlogisticsenhance scalability and quality compliance across the supply chain.
— Home-Based Care Trend:Growth of prefilled syringes and on-body injectors supports patient self-administration.
SegmentationInsights
Thegeneric injectables marketis segmented by molecule type,producttype, route of administration, therapeutic area,distribution channel,and geography.
— By molecule type, small molecules continue to dominate market share, while biosimilar injectables arewitnessingaccelerated adoption.
— Vials and prefilled syringes lead theproduct segment, supported by ongoing innovation in ready-to-administer packaging.
By Product Type
— Vials
— Ampoules
— Prefilled Syringes
— Cartridges
— IV Bags & Large-VolumeParenteral
By Molecule Type
— Small-Molecule Generics
— Large-Molecule/Biosimilar Generics
By Therapeutic Area
— Oncology
— Anti-infectives
— Cardiovascular
— Diabetes & Metabolic
— CNS Disorders
— Others
By Route of Administration
— Intravenous
— Intramuscular
— Sub-cutaneous
— Others
By Distribution Channel
— Hospital Pharmacies
— Retail & Mail-order Pharmacies
— Online Pharmacies
To know more about the segments driving the market growth, visit -https://www.mordorintelligence.com/industry-reports/generic-injectables-market?utm_source=prnewswire
Regional Market Dynamics
North America leads the globalgeneric injectables market, backed by strong FDA approvals andestablishedmanufacturing infrastructure. Europe follows with expanded biosimilar adoption and centralized procurement programs. Asia-Pacific isemergingas a high-growth region, driven by government incentives, rising domestic production capacity, and increasing healthcare expenditure.
North America
— United States
— Canada
— Mexico
Europe
— Germany
— United Kingdom
— France
— Italy
— Spain
— Rest of Europe
Asia-Pacific
— China
— Japan
— India
— Australia
— South Korea
— Rest of Asia-Pacific
Middle East & Africa
— GCC
— South Africa
— Rest of Middle East & Africa
South America
— Brazil
— Argentina
— Rest of South America
CompetitiveEnvironment
The marketremainsmoderatelyconsolidated, with global and regional players focusing on cost leadership, sterile manufacturing expansion, and portfolio diversification. Strategic alliances and partnerships for biosimilar injectables are increasingly shaping the competitive environment.
Prominent companiesoperatingin thegeneric injectables marketinclude:
— Fresenius Kabi
— Pfizer
— Viatris
— Hikma Pharmaceuticals
— Teva Pharmaceuticals
Industry Related Reports
Injectable Anti-diabetic Drugs Market:The injectable anti-diabetic drugs market report is segmented by drug class (insulin [basal/long-acting], GLP-1receptor agonists), diabetes type (type-1 diabetes, type-2 diabetes), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), age group (adults, geriatric, pediatric), and geography(North America, Europe, Asia-Pacific, Middle East & Africa, South America).
Muscle Relaxant Drugs Market:Themuscle relaxant drugs market report is segmented by drug type (facial aesthetic relaxants, skeletal muscle relaxants), formulation (oral, injectable, transdermal/topical), distribution channel (hospital pharmacy, retail pharmacy, online pharmacy), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America).
Injection Pen Market:The Injection pen market report is segmented by product type (disposable, reusable, smart/connected), indication (diabetes, autoimmune diseases, growth hormone deficiency, oncology supportive care, osteoporosis, other indications), distribution channel (hospital pharmacies), and geography(North America, Europe, Asia-Pacific, Middle East & Africa, South America).
About MordorIntelligence:
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries,Mordor Intelligencepossessesa unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries, please contact:media@mordorintelligence.comhttps://www.mordorintelligence.com/contact-us
Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg
https://edge.prnewswire.com/c/img/favicon.png?sn=IO39359&sd=2025-12-04
View original content:https://www.prnewswire.com/news-releases/generic-injectables-market-dominated-by-hospital-pharmacies-with-61-23-share-as-online-pharmacies-surge-at-18-06-cagr-through-2030–reports-mordor-intelligence-302632868.html
SOURCE Mordor Intelligence Private Limited
https://rt.newswire.ca/rt.gif?NewsItemId=IO39359&Transmission_Id=202512040442PR_NEWS_USPR_____IO39359&DateId=20251204